A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

[1]  R. Montgomery,et al.  Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  D. Lewandowski,et al.  Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  Jeffrey S. Stonebraker,et al.  A study of variations in the reported haemophilia B prevalence around the world , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  A. Shapiro,et al.  Modern haemophilia care , 2012, The Lancet.

[5]  S. Watson,et al.  A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control , 2012, Diabetes.

[6]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[7]  C. Hay,et al.  The principal results of the International Immune Tolerance Study: a randomized dose comparison. , 2012, Blood.

[8]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[9]  A. Neff,et al.  Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  K. Fischer,et al.  Clinical severity of haemophilia A: does the classification of the 1950s still stand? , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  V. Jiménez‐Yuste,et al.  When should prophylaxis therapy in inhibitor patients be considered? , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  K. High,et al.  Gene therapy for haemophilia: a long and winding road , 2011, Journal of thrombosis and haemostasis : JTH.

[13]  Kunihiro Hattori,et al.  Engineering the variable region of therapeutic IgG antibodies , 2011, mAbs.

[14]  K. Ghosh,et al.  Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. , 2011, Autoimmunity reviews.

[15]  Saileta Prabhu,et al.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.

[16]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[17]  D. Lillicrap.  Improvements in factor concentrates , 2010, Current opinion in hematology.

[18]  Lawren C. Wu,et al.  Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.

[19]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[20]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[21]  T. Igawa,et al.  Reduced elimination of IgG antibodies by engineering the variable region. , 2010, Protein engineering, design & selection : PEDS.

[22]  Jeffrey S. Stonebraker,et al.  A study of variations in the reported haemophilia A prevalence around the world , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  P. Kufer,et al.  BiTE: Teaching antibodies to engage T-cells for cancer therapy. , 2009, Current opinion in molecular therapeutics.

[24]  E. Zorrilla,et al.  Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice , 2008, Proceedings of the National Academy of Sciences.

[25]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[26]  Tomoko Matsumoto,et al.  New assays for monitoring haemophilia treatment , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  B. Shen,et al.  The tertiary structure and domain organization of coagulation factor VIII. , 2008, Blood.

[28]  V. Stoll,et al.  A potent erythropoietin-mimicking human antibody interacts through a novel binding site. , 2007, Blood.

[29]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[30]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[31]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[32]  J. Maahs,et al.  Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  M. Okuda,et al.  Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. , 2004, Clinical and laboratory haematology.

[34]  P. Fay.  Activation of factor VIII and mechanisms of cofactor action. , 2004, Blood reviews.

[35]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[36]  Robyn L Stanfield,et al.  Contrasting IgG structures reveal extreme asymmetry and flexibility. , 2002, Journal of molecular biology.

[37]  J. Oldenburg,et al.  Inhibitor development in correlation to factor VIII genotypes , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  K. Koshibu,et al.  The A2 Subunit of Factor VIIIa Modulates the Active Site of Factor IXa* , 1998, The Journal of Biological Chemistry.

[40]  Camellia W. Adams,et al.  An efficient route to human bispecific IgG , 1998, Nature Biotechnology.

[41]  M. Madanat,et al.  Intrachain disulfide bond in the core hinge region of human IgG4 , 1997, Protein science : a publication of the Protein Society.

[42]  P. Fay,et al.  Localization of a Factor X Interactive Site in the A1 Subunit of Factor VIIIa* , 1997, The Journal of Biological Chemistry.

[43]  J. Healey,et al.  The cDNA and derived amino acid sequence of porcine factor VIII. , 1996, Blood.

[44]  P. Lenting,et al.  Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. , 1994, The Journal of biological chemistry.

[45]  Y. Tajima,et al.  Efficient production of recombinant human factor VIII by co-expression of the heavy and light chains. , 1993, Protein engineering.

[46]  J. Stockman.  Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors , 2013 .

[47]  C. Hancock.  The long and winding road , 2005, Nature Reviews Drug Discovery.

[48]  Y G Meng,et al.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.

[49]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.